<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-235 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-235</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-235</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-5.html">extraction-schema-5</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-21335389</p>
                <p><strong>Paper Title:</strong> Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement</p>
                <p><strong>Paper Abstract:</strong> The objectives of this study were to determine the proportions of major oncogenic alterations and to examine survival in genotype‐specific subsets of never‐smokers with nonsmall cell lung cancer (NSCLC).</p>
                <p><strong>Cost:</strong> 0.013</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e235.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e235.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR prevalence (East Asian LCINS)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor (EGFR) mutation prevalence in East Asian never-smoker lung cancer patients (this study)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>This study measured EGFR mutation frequency by sequencing exons 18-21 in 229 Korean never-smokers with NSCLC and reports a high prevalence of activating EGFR mutations, with clinicopathologic correlates and discussion of ethnic comparisons from the literature.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Distinct Clinical Features and Outcomes in Never-Smokers With Nonsmall Cell Lung Cancer Who Harbor EGFR or KRAS Mutations or ALK Rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>229 consecutive never-smokers with newly diagnosed, histologically confirmed NSCLC enrolled at Yonsei Cancer Center, Seoul, Korea; ethnicity: East Asian (Korean); sex: 30 men, 199 women; median age 58 (range 30-78).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_type</strong></td>
                            <td>Activating EGFR kinase-domain alterations detected by sequencing of exons 18-21: predominant exon 19 deletions (69/110, 62.7%) and exon 21 L858R point mutations (37/110, 33.6%); rare double mutations (including T790M combinations) and one exon 20 duplication reported.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_asian</strong></td>
                            <td>48% (110/229) in this East Asian (Korean) never-smoker cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_non_asian</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_comparative_ethnic_data</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_smoking_status</strong></td>
                            <td>All patients were never-smokers (defined as lifetime tobacco exposure <100 cigarettes).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Predominantly adenocarcinoma (215/229 overall; EGFR-mutant tumors overwhelmingly adenocarcinomas: 105/110 EGFR-mutant cases were adenocarcinoma).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>The paper cites prior work implicating environmental tobacco smoke (passive smoking) in influencing EGFR mutation incidence (reference: Lee et al. J Clin Oncol 2010) but does not provide new exposure data in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>Authors discuss possible ethnic/genetic differences as an explanation for observed mutation spectra and cite germline susceptibility loci in the literature (e.g., 5p15.33, 6p21.33, 15q25.1 referenced) but do not present primary germline data in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>No single mechanistic cause is proven in this paper; suggested explanations include (a) LCINS is often driven by single oncogene 'addiction' (favoring EGFR driver events), (b) differences in mutational processes between smokers and never-smokers (e.g., transition vs transversion patterns), and (c) possible ethnic/genetic predisposition and/or environmental exposures (passive smoke or other non-tobacco carcinogens) influencing mutation prevalence.</td>
                        </tr>
                        <tr>
                            <td><strong>odds_ratio_or_risk</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Authors note potential confounders affecting apparent prevalence across studies: differences in mutation-detection sensitivity (direct sequencing false negatives), inclusion of smokers in comparative cohorts, small sample sizes in some reports, referral/selection bias, differences in treatment lines and therapies when comparing outcomes, and unmeasured environmental exposures.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>In an East Asian (Korean) cohort of never-smoker NSCLC patients, EGFR mutations were frequent (48%), dominated by exon 19 deletions and exon 21 L858R, and were associated with markedly better response and progression-free survival on EGFR TKIs; the paper emphasizes that EGFR mutations are a major defining oncogenic subset in East Asian LCINS and discusses (from the literature) that EGFR mutation frequencies appear higher in East Asian never-smokers compared with many historical non-Asian series, although this study did not perform a direct ethnic comparison.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e235.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e235.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS vs EGFR ethnic patterns</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Reported ethnic differences in KRAS and EGFR mutation frequencies (comparison literature and this East Asian cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper reports low KRAS mutation frequency in this East Asian never-smoker cohort and cites prior literature showing higher KRAS prevalence in Caucasian never-smokers, using these contrasts to argue for ethnic differences in mutation spectra and distinct mutational mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Distinct Clinical Features and Outcomes in Never-Smokers With Nonsmall Cell Lung Cancer Who Harbor EGFR or KRAS Mutations or ALK Rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>This paper's cohort: 229 East Asian (Korean) never-smokers with NSCLC (same as above). Comparative values are taken from cited literature rather than from within-study multi-ethnic comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_type</strong></td>
                            <td>As above for EGFR (exon 19 deletions and exon 21 L858R predominant). For KRAS, all observed KRAS mutations in this cohort were transition mutations at codon 12.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_asian</strong></td>
                            <td>KRAS mutations 3.5% (8/229) in this East Asian never-smoker cohort; EGFR mutations 48% (110/229).</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_non_asian</strong></td>
                            <td>The paper cites a prior report of KRAS mutations occurring in ~15% of Caucasian never-smokers (reference: Riely et al., Clin Cancer Res. 2008). The paper does not provide a direct numeric EGFR prevalence for Caucasians.</td>
                        </tr>
                        <tr>
                            <td><strong>has_comparative_ethnic_data</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_smoking_status</strong></td>
                            <td>All patients in this cohort were never-smokers; referenced comparative KRAS prevalence (15%) pertains to Caucasian never-smokers from the literature.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>KRAS-mutant tumors in this cohort were largely adenocarcinomas (6/8 KRAS cases were adenocarcinoma); EGFR-mutant tumors were predominantly adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>No direct environmental exposure data for KRAS in this study; discussion notes that mutational type (transition vs transversion) differs by smoking exposure and may reflect environmental mutagens.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>Authors suggest ethnic differences may reflect genetic background (ancestry-related predisposition) but do not present germline genetic data; they reference studies of germline susceptibility loci in never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>KRAS mutations in never-smokers are predominantly transition mutations (distinct from transversion-rich KRAS mutations in smokers), implying differing mutational processes; ethnic differences in KRAS frequency may therefore reflect different exposures or inherited susceptibility, though no definitive mechanism is provided.</td>
                        </tr>
                        <tr>
                            <td><strong>odds_ratio_or_risk</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Small numbers of KRAS-positive cases in the current East Asian cohort; cross-study comparisons limited by differences in detection methods, cohort composition (smoking mix), sample size, and study design.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>This East Asian never-smoker cohort had a low KRAS frequency (3.5%) compared with ~15% reported in Caucasian never-smokers in prior studies; all KRAS mutations here were transition mutations, supporting the concept that mutational spectra and overall driver frequencies differ by smoking status and may vary by ethnicity, with EGFR being the dominant driver in East Asian LCINS.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e235.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e235.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Environmental tobacco smoke (reference)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Impact of environmental tobacco smoke on EGFR mutation incidence (referenced study)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper cites prior work examining whether passive smoking (environmental tobacco smoke) affects EGFR mutation incidence in never-smokers, suggesting environmental exposures may modulate mutation prevalence.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Distinct Clinical Features and Outcomes in Never-Smokers With Nonsmall Cell Lung Cancer Who Harbor EGFR or KRAS Mutations or ALK Rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not studied directly in this paper; the cited reference (Lee YJ et al., J Clin Oncol 2010) examined never-smoker patients and environmental tobacco smoke exposure in relation to EGFR mutations (details not reproduced here).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_asian</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_non_asian</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_comparative_ethnic_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_smoking_status</strong></td>
                            <td>Relevant to never-smokers (passive exposure assessed in the cited work).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Specifically environmental tobacco smoke (passive smoking) is mentioned as a factor assessed in the cited literature as potentially influencing EGFR mutation incidence.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Implied hypothesis that passive tobacco exposure could induce mutation patterns or select for EGFR-mutant tumors among never-smokers, but not evaluated within this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>odds_ratio_or_risk</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Paper references environmental tobacco smoke as a potential factor but does not provide primary data; measurement and recall of passive exposure and co-exposures are typical confounders in such studies.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Environmental tobacco smoke is discussed in the context of prior literature as a possible contributor to EGFR mutation incidence in never-smokers, but this study did not directly test that association.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases <em>(Rating: 2)</em></li>
                <li>Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with nonsmall-cell lung cancer <em>(Rating: 2)</em></li>
                <li>Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications <em>(Rating: 2)</em></li>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>